Search

Your search keyword '"Eskiocak, Ugur"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Eskiocak, Ugur" Remove constraint Author: "Eskiocak, Ugur"
48 results on '"Eskiocak, Ugur"'

Search Results

3. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

6. Data from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

7. Supplementary Tables S1-S15 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

8. Supplementary Text, Figure Legends, Figures S1-S12 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

9. Supplementary Methods from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

11. Supplementary Figures 1-8, Tables 1-5, Methods from Functional Parsing of Driver Mutations in the Colorectal Cancer Genome Reveals Numerous Suppressors of Anchorage-Independent Growth

12. Abstract B04: Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors

13. 1325 Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T Cell engager for treatment of metastatic castration-resistant prostate cancer

14. 1123 Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors

22. Label-free detection of telomerase activity using guanine electrochemical oxidation signal

23. Gliomas Interact with Non-glioma Brain Cells via Extracellular Vesicles

24. 587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models

25. 568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates

26. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells

28. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity

29. Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models

30. Butyrophilin 3A1 is a Dynamic T Cell Regulator in Ovarian Cancer

31. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

33. Selective targeting of mutant adenomatous polyposis coli ( APC ) in colorectal cancer

34. Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma

35. Abstract 2881: Deubiquitinase Usp9x controls tumorigenicity through regulation of the Ets-1 transcription factor in melanoma

41. Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.

45. Stable Down-Regulation of Putative Colorectal Cancer Candidate Genes Identifies Extensive Fragility in the Matrix-Dependent Proliferation Control Network

48. Arrayed shRNA Screening to Identify Suppressors of Anchorage-Independent Growth.

Catalog

Books, media, physical & digital resources